Aldeyra dry eye disease candidate hit by FDA delay amid shifting agency guidance, biotech says
Fuente:
FierceBiotech
The FDA has delayed an approval decision for Aldeyra Therapeutics’ lead dry eye disease candidate, adding another detour to the candidate’s winding road to potentially reach the market.